## Marta Bosia

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7017026/publications.pdf

Version: 2024-02-01

304743 345221 1,605 89 22 36 citations h-index g-index papers 97 97 97 2167 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophrenia Research, 2009, 114, 154-160.	2.0	137
2	The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. Comprehensive Psychiatry, 2016, 71, 106-120.	3.1	108
3	Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neuroscience Letters, 2007, 417, 271-274.	2.1	90
4	Theory of mind and emotion processing training for patients with schizophrenia: Preliminary findings. Psychiatry Research, 2012, 198, 371-377.	3.3	62
5	Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour. Psychiatry Research, 2017, 251, 118-124.	3.3	58
6	â€Theory' of mind impairment in patients affected by schizophrenia and in their parents. Schizophrenia Research, 2009, 115, 278-285.	2.0	57
7	Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment. Psychiatry Research, 2014, 217, 9-14.	3.3	57
8	Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. Neuroscience Letters, 2012, 522, 151-155.	2.1	53
9	Theory of Mind intervention for outpatients with schizophrenia. Neuropsychological Rehabilitation, 2013, 23, 383-400.	1.6	47
10	Neurofunctional Correlates of Theory of Mind Deficits in Schizophrenia. Current Topics in Medicinal Chemistry, 2012, 12, 2284-2302.	2.1	39
11	<i>COMT</i> Val158Met and <i>5-HT1A-R</i> -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics, 2015, 16, 35-44.	1.3	37
12	Detecting syntactic and semantic anomalies in schizophrenia. Neuropsychologia, 2015, 79, 147-157.	1.6	37
13	Integrated cognitive remediation and standard rehabilitation therapy in patients of schizophrenia: persistence after 5 years. Schizophrenia Research, 2018, 192, 335-339.	2.0	35
14	Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. Psychological Medicine, 2015, 45, 3147-3157.	4.5	34
15	Computer-aided neurocognitive remediation in schizophrenia: Durability of rehabilitation outcomes in a follow-up study. Neuropsychological Rehabilitation, 2010, 20, 659-674.	1.6	33
16	HTTLPR functional polymorphism in schizophrenia: Executive functions vs. sustained attention dissociation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 81-85.	4.8	31
17	Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. European Psychiatry, 2014, 29, 219-225.	0.2	28
18	Self-awareness of cognitive functioning in schizophrenia: Patients and their relatives. Psychiatry Research, 2012, 198, 207-211.	3.3	25

#	Article	lF	CITATIONS
19	Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics, 2014, 15, 925-932.	1.3	25
20	A leopard cannot change its spots: A novel pragmatic account of concretism in schizophrenia. Neuropsychologia, 2020, 139, 107332.	1.6	25
21	Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry, 2012, 27, 396-400.	0.2	24
22	Patterns of evidence integration in schizophrenia and delusion. Psychiatry Research, 2012, 200, 108-114.	3.3	24
23	Intellectual and cognitive profiles in patients affected by schizophrenia. Journal of Neuropsychology, 2019, 13, 589-602.	1.4	24
24	Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry Research, 2011, 188, 187-190.	3.3	23
25	Targeting anxiety to improve quality of life in patients with schizophrenia. European Psychiatry, 2017, 45, 129-135.	0.2	23
26	Cognitive Remediation and Functional Improvement in Schizophrenia: is it a Matter of Size?. European Psychiatry, 2017, 40, 26-32.	0.2	23
27	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	1.3	23
28	Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry, 2013, 13, 235.	2.6	20
29	Achieving recovery in patients with schizophrenia through psychosocial interventions: <scp>A</scp> retrospective study. Psychiatry and Clinical Neurosciences, 2018, 72, 28-34.	1.8	20
30	COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychology and Behavioral Medicine, 2014, 2, 509-516.	1.8	19
31	Combined Neurocognitive And Metacognitive Rehabilitation In Schizophrenia: Effects On Bias Against Disconfirmatory Evidence. European Psychiatry, 2015, 30, 615-621.	0.2	19
32	Cognitive Reserve Profiles in Chronic Schizophrenia: Effects on Theory of Mind Performance and Improvement after Training. Journal of the International Neuropsychological Society, 2018, 24, 563-571.	1.8	18
33	It is time to address language disorders in schizophrenia: A RCT on the efficacy of a novel training targeting the pragmatics of communication (PragmaCom). Journal of Communication Disorders, 2022, 97, 106196.	1.5	18
34	Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. Frontiers in Psychiatry, 2018, 9, 647.	2.6	17
35	From cognitive and clinical substrates to functional profiles: Disentangling heterogeneity in schizophrenia. Psychiatry Research, 2019, 271, 446-453.	3.3	17
36	Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. Comprehensive Psychiatry, 2013, 54, 181-186.	3.1	16

#	Article	IF	Citations
37	The Influence of Premorbid Adjustment and Autistic Traits on Social Cognitive Dysfunction in Schizophrenia. Journal of the International Neuropsychological Society, 2020, 26, 276-285.	1.8	16
38	Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opinion on Drug Discovery, 2015, 10, 125-139.	5.0	15
39	Communicative-pragmatic abilities mediate the relationship between cognition and daily functioning in schizophrenia Neuropsychology, 2021, 35, 42-56.	1.3	15
40	COMT and STH polymorphisms interaction on cognition in schizophrenia. Neurological Sciences, 2015, 36, 215-220.	1.9	12
41	Is longer treatment better? A comparison study of 3 versus 6 months cognitive remediation in schizophrenia Neuropsychology, 2017, 31, 467-473.	1.3	12
42	Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. Schizophrenia Research, 2018, 202, 106-110.	2.0	12
43	ADDing a piece to the puzzle of cognition in schizophrenia. European Journal of Medical Genetics, 2016, 59, 26-31.	1.3	11
44	Exploring anxiety in schizophrenia: New light on a hidden figure. Psychiatry Research, 2018, 268, 312-316.	3.3	11
45	The role of premorbid adjustment in schizophrenia: Focus on cognitive remediation outcome. Neuropsychological Rehabilitation, 2019, 29, 1611-1624.	1.6	11
46	Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex. Psychiatry Research, 2021, 297, 113698.	3.3	10
47	Can patients with schizophrenia have good mentalizing skills? Disentangling heterogeneity of theory of mind Neuropsychology, 2018, 32, 746-753.	1.3	10
48	Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. Schizophrenia Research: Cognition, 2014, 1, 187-192.	1.3	9
49	Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 363-368.	4.8	9
50	Functional benefits of co-occurring autistic symptoms in schizophrenia is delimited by symptom severity. Journal of Psychiatric Research, 2021, 137, 48-54.	3.1	9
51	Eyes wide open: A systematic review of the association between insomnia and aggression in forensic contexts. International Journal of Law and Psychiatry, 2021, 78, 101734.	0.9	9
52	Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?. Journal of Psychiatric Research, 2021, 141, 346-352.	3.1	9
53	Saitohin polymorphism and executive dysfunction in schizophrenia. Neurological Sciences, 2012, 33, 1051-1056.	1.9	8
54	Exploring predictors of work competence in schizophrenia: The role of theory of mind. Neuropsychological Rehabilitation, 2019, 29, 691-703.	1.6	7

#	Article	IF	Citations
55	Communication in schizophrenia, between pragmatics, cognition, and social cognition. Linguistik Aktuell, 0, , 213-234.	0.6	7
56	Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence. Journal of Pineal Research, 2022, 72, .	7.4	7
57	Visual and audio emotion processing training for outpatients with schizophrenia: an integrated multisensory approach. Neuropsychological Rehabilitation, 2018, 28, 1131-1144.	1.6	6
58	The association of autistic traits with Theory of Mind and its training efficacy in patients with schizophrenia. Schizophrenia Research: Cognition, 2020, 19, 100164.	1.3	6
59	Stability and generalization of combined theory of mind and cognitive remediation interventions in schizophrenia: Follow-up results Psychiatric Rehabilitation Journal, 2020, 43, 140-148.	1.1	5
60	Daily Functioning in Schizophrenia. Journal of Nervous and Mental Disease, 2019, 207, 615-619.	1.0	4
61	The role of genetics in cognitive remediation in schizophrenia: A systematic review. Schizophrenia Research: Cognition, 2020, 19, 100146.	1.3	4
62	Theory of mind and stereotypic behavior promote daily functioning in patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 2022, 56, 818-827.	2.3	4
63	On the Implementation of Computerized Adaptive Observations for Psychological Assessment. Assessment, 2022, 29, 225-241.	3.1	3
64	Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia Research, 2022, 239, 34-41.	2.0	3
65	Modeling the interplay of age at onset and sex on cognition in schizophrenia. Asian Journal of Psychiatry, 2022, , 103202.	2.0	3
66	P.3.14 Association study of COMT Val108/158Met polymorphism and treatment response to haloperidol, risperidone and clozapine. European Neuropsychopharmacology, 2009, 19, S73-S74.	0.7	2
67	9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology Psychiatry and Brain Research, 2012, 18, 109-113.	2.0	2
68	Cognition in Schizophrenia: Modeling the Interplay between Interleukin- $1\hat{l}^2$ C-511T Polymorphism, Metabolic Syndrome, and Sex. Neuropsychobiology, 2021, 80, 321-332.	1.9	2
69	Cognitive remediation in schizophrenia: What happens after 10 years?. Schizophrenia Research: Cognition, 2022, 29, 100251.	1.3	2
70	Research Highlights: Highlights from the latest research in mood disorder pharmacogenomics. Pharmacogenomics, 2013, 14, 127-130.	1.3	1
71	M51. EFFICACY OF "PRAGMACOM TRAINING―IN SCHIZOPHRENIA: A RCT ON A NOVEL PRAGMATIC INTERVENTION. Schizophrenia Bulletin, 2020, 46, S153-S153.	4.3	1
72	M202. SEX-RELATED DIFFERENCES IN CLOZAPINE SIDE EFFECTS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S213-S213.	4.3	1

#	Article	IF	Citations
73	Cognitive Remediation for Inpatients With Schizophrenia. Journal of Nervous and Mental Disease, 2021, 209, 76-81.	1.0	1
74	P.3.12 Association study of GSK-3 $\hat{l}^2$ $\hat{a}^{\circ}$ 50T/C polymorphism with executive performances in schizophrenia. European Neuropsychopharmacology, 2007, 17, S79.	0.7	0
75	P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine. European Neuropsychopharmacology, 2009, 19, S546-S547.	0.7	O
76	EXECUTIVE DYSFUNCTION IN SCHIZOPHRENIA: POSSIBLE ROLE OF SAITOHIN GENE. Schizophrenia Research, 2010, 117, 217.	2.0	0
77	P.3.a.016 Effects of catechol-O-methyltransferase Val108/158Met and Saitohin q7r polymorphisms on cognitive functions in schizophrenia. European Neuropsychopharmacology, 2011, 21, \$462.	0.7	O
78	S.09.02 Predicting cognitive remediation outcome with genes. European Neuropsychopharmacology, 2012, 22, S125-S126.	0.7	0
79	P.3.a.014 Exploring the effect of genetic variability of adducins on cognition in schizophrenia. European Neuropsychopharmacology, 2012, 22, S311-S312.	0.7	0
80	P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms. European Neuropsychopharmacology, 2013, 23, S446.	0.7	0
81	Research Highlights: Highlights from the latest articles on the pharmacogenomics of neuropsychiatric disorders. Pharmacogenomics, 2014, 15, 735-738.	1.3	0
82	P.3.b.034 Interaction of EAAT2 genotype and clozapine on cognitive remediation outcome. European Neuropsychopharmacology, 2014, 24, S511.	0.7	0
83	Tough Love: Sexuality, Compassion, and the Christian Right. By Cynthia Burack . Albany, NY: SUNY Press, 2014. 257 pp. \$85.00 cloth. \$29.95 eBook. Politics and Religion, 2015, 8, 181-183.	0.8	0
84	S67. TREATMENT-RESISTANCE AFFECTS LONG-TERM COGNITIVE TRAJECTORIES IN SCHIZOPHRENIA: A LONGITUDINAL STUDY. Schizophrenia Bulletin, 2020, 46, S59-S59.	4.3	0
85	P.205 White matter integrity, clinical symptoms and quality of life in schizophrenia: a DTI study. European Neuropsychopharmacology, 2021, 44, S19-S20.	0.7	0
86	Disentangling Cognitive Heterogeneity in Psychotic Spectrum Disorders. Asian Journal of Psychiatry, 2021, 60, 102651.	2.0	0
87	Targeting the communicative impairment in schizophrenia with a neuropragmatic approach. Frontiers in Psychology, 0, 8, .	2.1	0
88	Obsessive-compulsive symptoms moderates the effects of cognitive functioning on quality of life in clozapine-treated schizophrenia. Psychiatry Research Communications, 2022, , 100043.	1.0	0
89	Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life. Schizophrenia Research: Cognition, 2022, 28, 100245.	1.3	0